Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Arbutus Biopharma Corp(ABUS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABUS
10/02/2026: ABUS (2-star) is a SELL. SELL for 4 days. Simulated Profits (-5.82%). Updated daily EoD!
Arbutus Biopharma is a clinical-stage biotechnology company dedicated to developing a functional cure for chronic hepatitis B. Its primary business strength lies in its proprietary lipid nanoparticle (LNP) delivery technology and a specialized pipeline of HBV-focused drug candidates. The main investment story centers on the potential for its clinical trials to prove efficacy where current treatments fail, offering significant upside in a massive market. However, the company faces substantial risks, including clinical trial failure, intense competition from large-cap pharmaceutical firms, and reliance on outside capital. Arbutus best suits investors with a high risk tolerance who are specifically looking for exposure to novel drug development milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk, high-reward bet on clinical success for a company currently lacking commercial revenue. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors often trade around clinical trial data releases and strategic partnership news. |
| Value investor | Weak fit | The company lacks the positive earnings and cash flows typically required by value investors. |
| Dividend investor | Weak fit | The company does not pay a dividend and requires cash for capital-intensive drug development. |
| Low-risk investor | Weak fit | High volatility and the binary nature of clinical outcomes make this unsuitable for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial announcements and legal outcomes. |
| Valuation risk | Medium / high | Valuation is speculative and based on the future probability of drug approval. |
| Competition risk (HBV therapeutics) | High | It competes against global giants with significantly larger R&D budgets. |
| Business quality | Medium | The business relies on proprietary technology and IP but lacks current commercial product sales. |
| Dividend income | Low / none | Income investors should not look here as the company reinvests all capital. |
| Execution risk | High | Success depends entirely on successfully navigating the multi-year clinical trial and regulatory approval process. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -28.95% | Avg. Invested days 34 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 903.36M USD | Price to earnings Ratio 6.08 | 1Y Target Price 5.36 |
Price to earnings Ratio 6.08 | 1Y Target Price 5.36 | ||
Volume (30-day avg) 7.7M shares | Beta 0.62 | 52 Weeks Range 3.50 - 5.45 | Updated Date 10/02/2026 |
52 Weeks Range 3.50 - 5.45 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.75 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Licensing and Royalties | Revenue derived from legacy and current LNP technology license agreements. | This is currently the company's only source of revenue, though it is not the core focus of future growth. |
| Clinical Development | The R&D effort for imdusarviran and other HBV candidates. | The company is spending money today in hopes of creating a blockbuster medical treatment tomorrow. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 6.08 | Forward PE 10.25 | Enterprise Value 868.70M | Price to Sales(TTM) 4.97 |
Enterprise Value 868.70M | Price to Sales(TTM) 4.97 | ||
Enterprise Value to Revenue 4.95 | Enterprise Value to EBITDA 5.87 | Shares Outstanding 198.11M | Shares Floating 122.36M |
Shares Outstanding 198.11M | Shares Floating 122.36M | ||
Percent Insiders 20.4 | Percent Institutions 72.41 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Arbutus Biopharma Corp
Exchange NASDAQ | Headquarters Warminster, PA, United States | ||
IPO Launch date 2015-08-03 | President, CEO & Chairman Ms. Lindsay Androski J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.arbutusbio.com |
Full time employees 19 | Website https://www.arbutusbio.com | ||
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.